NCT03061955View on ClinicalTrials.gov

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

CompletedOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

April 26, 2019

Conditions
Influenza Virus Vaccine Adverse Reaction (Disorder)InfluenzaMalignancy
Interventions
BIOLOGICAL

influenza vaccination

administration of influenza vaccination

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT03061955 - Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab) | Biotech Hunter | Biotech Hunter